Skip to main content

SMMT

Stock
Health Care
Biotechnology

Performance overview

SMMT Price
Price Chart

Forward-looking statistics

Beta
0.92
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

summit is a uk company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. our strategy focuses on two therapy areas: duchenne muscular dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria c. difficile.

Company info

SectorHealth Care
IndustryBiotechnology
Employees101
Market cap$5.4B

Fundamentals

Enterprise value$15.4B
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity1.87

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)-$0.34
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$147M
Avg trading volume (10 day)$140M
Put-call ratio

Macro factor sensitivity

Growth-1.5
Credit+3.7
Liquidity-4.0
Inflation-1.7
Commodities-1.6
Interest Rates+0.6

Valuation

Dividend yield0.00%
PEG Ratio-64.61
Price to sales
P/E Ratio-64.61
Enterprise Value to Revenue
Price to book52.91

Upcoming events

Next earnings dayMay 2, 2025
Next dividend day
Ex. dividend day

News

SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca

Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.

Zacks Investment Research (July 7, 2025)
Is SMMT Stock A Buy After Its Recent Plunge?

Summit Therapeutics (NASDAQ: SMMT) experienced a significant 30% decrease in its stock on Friday, May 30th, closing at $18. This sudden decline came even though the stock had doubled within the past year, driven by favorable updates regarding its lung cancer medication, ivonescimab.

Forbes (June 2, 2025)
Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint

Summit Therapeutics Inc. SMMT released topline results on Friday from the Phase 3 HARMONi trial of ivonescimab plus platinum-doublet chemotherapy compared to placebo plus platinum-doublet chemotherapy for epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with a 3rd generation EGFR tyrosine kinase inhibitor (TKI).

Benzinga (May 30, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free